脂质体布比卡因浅层胸骨旁肋间平面阻滞未显著减少心脏术后阿片类药物用量:随机临床试验
这项前瞻性随机双盲对照试验纳入100例经正中胸骨切开的择期冠脉搭桥或瓣膜手术患者,比较切皮前双侧浅层胸骨旁肋间平面(SPIP)阻滞使用布比卡因与脂质体布比卡因混合液与生理盐水安慰剂的效果。主要结局为术后72小时总阿片类药物消耗量(口服吗啡毫克当量,MME),结果显示两组无显著差异(165 vs 205 MME,p=0.30),疼痛评分、拔管时间、ICU及住院时长和90天阿片使用亦相似。结论提示单次注射SPIP阻滞加脂质体布比卡因在心脏手术患者中可能不如重复注射或导管技术有效。
要点
- 切皮前双侧SPIP阻滞加脂质体布比卡因未减少术后72小时阿片消耗。
- 疼痛评分、拔管时间、ICU及住院时长和90天阿片使用组间无差异。
- 单次注射SPIP阻滞在心脏手术中可能不如重复注射或导管技术有效。
核心结论
- 切皮前双侧SPIP阻滞使用布比卡因与脂质体布比卡因混合液未显著减少心脏手术患者阿片消耗或改善术后镇痛结局。
- 单次注射SPIP阻滞加脂质体布比卡因在心脏手术患者中可能不如重复注射或导管技术有效。
研究设计与样本
- 前瞻性、随机、双盲、对照试验,纳入100例经正中胸骨切开的择期冠脉搭桥或瓣膜手术患者。
- 患者随机接受切皮前双侧SPIP阻滞,使用布比卡因与脂质体布比卡因混合液或生理盐水安慰剂。
- 主要结局为术后72小时总阿片消耗量(口服吗啡毫克当量,MME)。
主要发现
- 术后72小时总阿片消耗量组间无显著差异:SPIP干预组165(IQR 103-284)MME vs 生理盐水安慰剂组205(IQR 145-282)MME,p=0.30。
- 疼痛评分、拔管时间、ICU及住院时长、90天阿片使用组间亦相似。
- 未报告严重不良事件。
临床怎么用
- 心脏手术多模式镇痛中,单次注射SPIP阻滞加脂质体布比卡因不应被常规期望显著减少阿片消耗。
- 可考虑重复注射或导管技术,或探索多节段注射、阻滞时机、替代局麻药及针对胸管相关疼痛的策略。
局限性
- 单中心研究,样本量100例。
- 仅评估单次注射SPIP阻滞,未涉及重复注射或导管技术。
- 未专门针对胸管相关疼痛设计干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute pain after cardiac surgery via median sternotomy is commonly managed with multimodal analgesia, but optimal regional techniques remain uncertain. Superficial parasternal intercostal plane (SPIP) blocks have shown promise for postoperative pain control, with the use of catheters extending these benefits up to three days. This study evaluated the efficacy of single-injection SPIP blocks with liposomal bupivacaine in reducing opioid consumption following cardiac surgery. METHODS: In this prospective, randomized, double-blind controlled trial, 100 patients undergoing elective coronary artery bypass grafting or valve surgery via median sternotomy were randomized to receive bilateral SPIP blocks with either a mixture of bupivacaine and liposomal bupivacaine or saline placebo prior to incision. The primary outcome was total opioid consumption in oral morphine milligram equivalents (MME) over the first 72 postoperative hours. Secondary outcomes included pain scores, time to extubation, intensive care unit (ICU) and hospital length of stay and opioid use at 90 days. RESULTS: Total opioid consumption in the first 72 hours was not significantly different between groups (SPIP intervention: 165 (IQR 103-284) MME vs saline placebo: 205 (IQR 145-282) MME, p=0.30). Pain scores, extubation time, ICU and hospital length of stay, and opioid use at 90 days were also similar between groups. No serious adverse events were reported. CONCLUSIONS: Preincision bilateral SPIP blocks with a mixture of bupivacaine and liposomal bupivacaine did not significantly reduce opioid consumption or improve postoperative analgesic outcomes compared with saline placebo in cardiac surgical patients. These findings suggest that single-injection SPIP blocks with liposomal bupivacaine may not be as effective as repeated injections or catheters in cardiac surgical patients. Further studies should explore modifications to block techniques such as multilevel injections, the timing of the block relative to surgery, alternative local anesthetics, and strategies specifically targeting chest tube-related pain. TRIAL REGISTRATION NUMBER: NCT04928339.
引用
- Simon ER, Mallery A, Silva J, et al. Superficial parasternal intercostal plane blocks with liposomal bupivacaine did not significantly reduce opioid use after cardiac surgery: a randomized clinical trial. Reg Anesth Pain Med. 2025. PMID: 40850695. doi:10.1136/rapm-2025-106952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。